Mechanism overviews · 29 papers
Peptidoteca
Readypep ↗
↳ Peptide Reference
Immune

Thymosin Alpha-1

Also known as: Tα1 · Thymalfasin

A 28-amino-acid peptide studied in immune-modulation and host-defence research models.

Written by Peptidoteca Research Desk·Reviewed by Peptidoteca Research Desk·Last reviewed 2026-06-14·4 sources

§ In brief

Thymosin Alpha-1 (also known as Tα1, Thymalfasin) is a 28-amino-acid peptide studied in immune-modulation and host-defence research models. It is supplied for laboratory research use only and is not approved for human or veterinary use. Its 28-residue amino-acid sequence is SDAAVDTSSEITTKDLKEKKEVVEEAEN.

What is Thymosin Alpha-1?

A 28-amino-acid peptide studied in immune-modulation and host-defence research models.

Thymosin Alpha-1 is catalogued here as a reference compound for immune-modulation and cellular-energy research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

How is Thymosin Alpha-1 studied?

Thymosin Alpha-1 appears in the immune-modulation and cellular-energy literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 primary papers on Thymosin Alpha-1, each tagged with its study type below. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Is Thymosin Alpha-1 approved for human use?

No. Thymosin Alpha-1 is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

What are the research limitations?

Most available evidence for Thymosin Alpha-1 is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Thymosin Alpha-1 is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.

§ Primary literature

  1. 1.Solmonese L (2025). The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. OncoTargets and Therapy.In-vitroIn an in-vitro model using human tumor cell lines and isolated immune cell subsets, Thymosin alpha-1 was reported to modulate the transcriptional profiles of immune cells, with the most pronounced changes observed in activated CD8+ T cells.
  2. 2.Nevo N (2022). Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma. International Immunopharmacology.Rodent studyIn a mouse model of peritoneal metastases from colonic carcinoma, thymosin alpha-1 studied as an adjuvant to hyperthermic intraperitoneal chemotherapy was reported to be associated with a T-helper-1 immune response and increased CD8+ T-cell infiltration, while no direct anti-tumor effect of the peptide alone was observed.
  3. 3.Bellet MM (2021). Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. European Journal of Medicinal Chemistry.Rodent studyIn murine models of cystic-fibrosis-related gut inflammation, thymosin alpha-1 was reported to be associated with restored intestinal barrier integrity and immune homeostasis, with anti-inflammatory effects extending to the pancreas and liver.
  4. 4.Dominari A (2020). Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology.ReviewThis review surveys the reported immunomodulatory properties of thymosin alpha-1 across the literature, summarizing proposed mechanisms involving T-cell maturation and innate immune signaling as described in preclinical and clinical reports.
Compound spec
Sequence
SDAAVDTSSEITTKDLKEKKEVVEEAEN
Length28 aa
ClassImmune
CAS62304-98-7
Research vial10 mg

For in-vitro research only. Not medical, clinical or dosing advice.